ASMQ FDC proves safe and efficacious to treat children in Africa with malaria

November 04, 2014

[New Orleans, USA, 4 November 2014] Presented today at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (ASMTH), results of a multi-centre clinical trial in Africa, launched in 2008, to test the efficacy and tolerability of Artesunate-Mefloquine fixed-dose combination (ASMQ FDC) in children under 5 years of age with uncomplicated falciparum malaria showed that ASMQ FDC is as safe and efficacious as Artemether-Lumefantrine (AL) FDC - Africa's most widely adopted treatment.

The Phase IV, open-label, randomized, controlled, non-inferiority clinical trial included 945 children under 5 years of age, who were followed for 63 days. ASMQ FDC was administered once a day during three days. The study was conducted in three African countries: Burkina Faso, Kenya, and Tanzania.

Topline efficacy results, based on WHO efficacy analysis parameters (polymerase chain reaction (PCR) corrected): - No concerns of tolerability were demonstrated with ASMQ or with AL Data in Africa on the combination (AS+MQ non fixed-dose) had previously demonstrated high efficacy, acceptable safety, and tolerability. Obtaining further clinical data on the combination of Artesunate with Mefloquine in children in Africa was recommended by the World Health Organization (WHO) and its Prequalification Programme. ASMQ FDC is one of several recommended ACTs that aim to delay the emergence of resistance to the individual drug components of the combination treatment. The treatment regimen is easier to administer by the fact that the two drugs are combined into one tablet that only requires once-a-day administration over three days (as compared to twice-a-day over three days for AL).

'The ASMQ fixed-dose combination has proven its importance among tools recommended by the WHO and can now be available to African children suffering from uncomplicated falciparum malaria', said Dr Bernard Pécoul, Executive Director of DNDi. 'Considering that a child dies every 30 seconds from malaria, we hope that governments in affected African countries will now take up this additional treatment option to ensure their populations have access to several ACTs.'

ASMQ FDC was originally developed by DNDi and the Brazilian government-owned pharmaceutical company Farmanguinhos/Fiocruz and was registered in Brazil in 2008. A South-South technology transfer between Farmanguinhos and Cipla, India, was achieved in 2010 to facilitate the implementation of ASMQ FDC worldwide and was pre-qualified by the WHO Prequalification Programme in 2012. ASMQ FDC is currently registered in Brazil, India, Myanmar, Malaysia, Vietnam, Tanzania, and Niger, and pending registration in 17 countries in Africa and Asia.
Study Funding & Partners

Funding for this study was provided to DNDi by the Swiss Agency for Development and Cooperation (SDC), Switzerland; European and Developing Countries Clinical Trials Partnerships (EDCTP); French Development Agency (AFD), France; Department for International Development (DFID), United Kingdom; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Médecins Sans Frontières (Doctors Without Borders); and the Fondation ARPE, Switzerland.

Partners in the study include: staff at study sites; study monitors; Data Safety Monitoring Committee (DSMC) ; Cardinal Systems, Paris, France; Epicentre, Mbarara, Uganda; CHUV, Lausanne, Switzerland; and Farmanguinhos, Brazil. Clinical investigators of the study were from the following partner institutions: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; Kenya Medical Research Institute (KEMRI), Kisumu, Kenya; National Institute for Medical Research, Korogwe, United Republic of Tanzania; Ifakara Health Institute, Bagamayo, United Republic of Tanzania; National Institute for Medical Research, Kilosa, United Republic of Tanzania; Centre for Clinical Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; and Drugs for Neglected Diseases initiative, Geneva, Switzerland.

About Malaria Since the year 2000, remarkable progress has been made in the fight against malaria, with a 42% reduction in deaths globally. The WHO estimates that in 2012 there were 207 million of cases of malaria, and that 627,000 deaths were attributable to the disease, mostly in Africa (90%). Children continue to be the worst affected, accounting for 77% of all deaths, with an estimated 462,000 deaths in African children under the age of five in 2012. Most deaths were due to Plasmodium falciparum, however P. vivax is increasingly recognized as a cause of severe malaria and death.


  • Simple prescription which is easy to use, based on once-daily administration

  • Dosage selection of the tablets allows for a simple and adapted regimen for children and adults

  • Adapted packaging

  • High compliance

  • WHO Prequalification in September 2012 (Cipla)

  • Registered in Brazil in 2008, India in 2011, Malaysia and Myanmar in 2012, Tanzania in 2013, Vietnam and Niger in 2014

  • Currently filed for registration in 17 additional countries in Africa and Asia

    About DNDi

    The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development (R&D) organization working to deliver new treatments for the most neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filaria, and paediatric HIV/AIDS. Since its inception in 2003, DNDi has delivered six new treatments: two fixed-dose antimalarials (ASAQ and ASMQ); nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness; sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa; a set of combination therapies for visceral leishmaniasis in Asia; and a paediatric dosage form of benznidazole for Chagas disease. DNDi was founded by Médecins Sans Frontières/Doctors without Borders (MSF), Indian Council of Medical Research, Kenya Medical Research Institute, Brazil's Oswaldo Cruz Foundation, Ministry of Health of Malaysia, and Institut Pasteur in France, with the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) as a permanent observer.

    Press Contacts:

    Ilan Moss, DNDi Communications Manager, DNDi North America (on-site at ASTMH)

    Mobile: +1-646-266-5216 / E-mail:

    Violaine Dallenbach, DNDi Press and Communications Manager (Europe)

    Mobile: +41 79 424 14 74 / E-mail:

    Renee Olende, DNDi Communications Manager, DNDi Africa

    Mobile: +254 705 639 909 / E-mail:

    Betina Moura, DNDi Communications Manager, DNDi Latin America

    Mobile: +55 21 98122 2798 / E-mail:

    Drugs for Neglected Diseases Initiative

    Related Malaria Articles from Brightsurf:

    Clocking in with malaria parasites
    Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

    Breakthrough in malaria research
    An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

    Scientists close in on malaria vaccine
    Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

    New tool in fight against malaria
    Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

    Malaria expert warns of need for malaria drug to treat severe cases in US
    The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

    Monkey malaria breakthrough offers cure for relapsing malaria
    A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

    Getting to zero malaria cases in zanzibar
    New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

    Widely used malaria treatment to prevent malaria in pregnant women
    A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

    Protection against Malaria: A matter of balance
    A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

    The math of malaria
    A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

    Read More: Malaria News and Malaria Current Events
  • is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to